Explore the words cloud of the EBODAC project. It provides you a very rough idea of what is the project "EBODAC" about.
The following table provides information about the project.
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
|Coordinator Country||United Kingdom [UK]|
|Total cost||20˙402˙786 €|
|EC max contribution||20˙328˙856 € (100%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2014-12-01 to 2020-11-30|
Take a look of project's partnership.
|1||LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER||UK (LONDON)||coordinator||3˙380˙902.00|
|2||WORLD VISION OF IRELAND LBG||IE (DUBLIN 6)||participant||13˙493˙437.00|
|3||GRAMEEN FOUNDATION USA||US (WASHINGTON)||participant||3˙454˙515.00|
|4||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment.
The EBODAC consortium consists of 4 partners: Janssen (EFPIA), London School of Hygiene and Tropical Medicine (LSHTM), World Vision of Ireland and Grameen Foundation . These partners have experience and expertise in:
• (Ebola) vaccine development and vaccine acceptance; m-health deployments for disease management in resource limited settings (Janssen) • Vaccine acceptance; risk management in health programs (LSHTM) • Mobile health deployments for emergency assistance; communication and training delivery in emergency settings (World Vision) • Mobile health software development and deployment in resource limited settings (Grameen)
As such, the EBODAC consortium is well placed to tackle the challenges associated with Ebola vaccine deployment, including: • Stigma related to Ebola infections • Lack of understanding and distrust versus vaccines in general in the local endemic communities • Two step prime/booster regimen for Ebola vaccine: risk for a ‘no show’ for the booster shot, risk for presenting for the booster shot too early or too late; risk for a different person presenting for the booster shot vs. the prime shot • People may be difficult to reach for the vaccine recall; People may live at a large distance from the health center where the vaccine is delivered • Risk for data on vaccine coverage to be fragmented, not existing or incorrect
The EBODAC consortium is committed to deliver: • A communication strategy that will optimize vaccine acceptance, supported by local anthropology research data • A platform, based on mobile phone technology, for Ebola vaccine recalls, information/education on Ebola and vaccines in general; and tracking of vaccination coverage • An identification tool to allow to match the identity of individuals in the prime and boost vaccine regimens • A training program in the local setting, and a helpdesk function, to support the m-health platform
|Test identification tool ready (for trial)||Demonstrators, pilots, prototypes||2019-11-15 10:09:01|
|Final platform ready (trial)||Other||2019-11-15 10:09:01|
|Technology components integrated (trial)||Other||2019-11-15 10:09:01|
|All privacy, regulatory and policy elements taken into account for trial (for each geography)||Documents, reports||2019-11-15 10:09:01|
|Technical deployment elements ready (trial)(for each geography)||Other||2019-11-15 10:09:01|
|Iris-Scan study including data||Documents, reports||2019-11-15 10:09:01|
|Content for Mobile Training and Support Service for health;workers ready||Documents, reports||2019-11-15 10:09:01|
|Message content developed for trial||Documents, reports||2019-11-15 10:09:01|
|Overview of data flow (for trial)||Documents, reports||2019-11-15 10:09:01|
|Test platform ready (trial)||Demonstrators, pilots, prototypes||2019-11-15 10:09:01|
Take a look to the deliverables list in detail: detailed list of EBODAC deliverables.
|year||authors and title||journal||last update|
Serge Masyn, Anneleen Vuchelen, Eva Santermans, Freya Rasschaert, Allieu Bangura, Wim Parys, Romain Rutten
Overcoming the challenges of iris scanning to identify minors (1â€“4Â years) in the real-world setting
published pages: , ISSN: 1756-0500, DOI: 10.1186/s13104-019-4485-8
|BMC Research Notes 12/1||2020-03-05|
Paula Mc Kenna, Geoffrey Babughirana, Monica Amponsah, Seth Gogo Egoeh, Evelyne Banura, Robert Kanwagi, Bobbi Gray
Mobile training and support (MOTS) serviceâ€”using technology to increase Ebola preparedness of remotely-located community health workers (CHWs) in Sierra Leone
published pages: 35-35, ISSN: 2306-9740, DOI: 10.21037/mhealth.2019.09.03
Geoffrey Babughirana, Robert Kanwagi (World Vision)
Making enabling technologies work in Prime-Boost vaccination programs
published pages: , ISSN: , DOI:
Luisa Enria, Shelley Lees, Elizabeth Smout, Thomas Mooney, Angus F. Tengbeh, Bailah Leigh, Brian Greenwood, Deborah Watson-Jones, Heidi Larson
Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone
published pages: , ISSN: 1471-2458, DOI: 10.1186/s12889-016-3799-x
|BMC Public Health 16/1||2019-11-15|
Per Egil Kummervold, William S. Schulz, Elizabeth Smout, Luis Fernandez-Luque, Heidi J. Larson
Controversial Ebola vaccine trials in Ghana: a thematic analysis of critiques and rebuttals in digital news
published pages: , ISSN: 1471-2458, DOI: 10.1186/s12889-017-4618-8
|BMC Public Health 17/1||2019-11-15|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBODAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EBODAC" are provided by the European Opendata Portal: CORDIS opendata.
Antibiotic Distribution and Recovery in TissueRead More
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More